12-OAHSA
Based on 1 Customer Validation
12-OAHSA is a component of olive oil. 12-OAHSA has oral activity, and improves glucose homeostasis in insulin resistant obese mice.
For research use only. We do not sell to patients.
- Purity : 99.0%
- CAS No.: 101901-73-9
- Formula: C36H68O4
- Molecular Weight:564.92
-
Storage:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-158584
13-OAHSAFAHFA -
HY-W709961
5-OAHSAEndogenous Metabolite -
HY-131934
9-OAHSAAnti-Inflammatory reagent -
HY-116193
5-PAHSAAnti-Inflammatory Agent -
HY-117586
9-PAHPAAntidiabetic/Anti-inflammatory Agent -
HY-131668
9-POHSAAnti-Inflammatory Agent -
HY-138177
Butyryl-Coenzyme A sodiumButyric Acid Derivative -
HY-158583
13-POHSAFAHFA -
HY-130434
12-SAHSAFAHFA -
HY-116193R
5-PAHSA (Standard)Anti-Inflammatory Agent -
HY-130352
9-SAHSAFAHFA -
HY-133851
10-PAHSAFatty Ester
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vitro
12-OAHSA (25 μM, 24 h) inhibits LPS-induced IL-1b, IL-6, Nos2, and Tnf-α in Raw 264.7 macrophages[1].
12-OAHSA (25 μM, 6 h) reduces IKKβ phosphorylation and increases phosphorylation of p65 in Raw 264.7 macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:10-week HFD induced obese C57BL/6 mice[1]
-
Dosage:30 mg/kg
-
Administration:p.o., for 10 d
-
Result:Decreased adipose tissue macrophage (ATMs), and CD4+ and CD8+ T lymphocytes in eWAT.
Inhibits obesity-induced adipose tissue inflammation.
Chemical Information
-
CAS No. 101901-73-9
-
Appearance Liquid
-
Molecular Weight 564.92
-
Formula C36H68O4
-
Color Colorless to light yellow
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(OC(CCCCCC)CCCCCCCCCCC(O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Solution, -20°C, 2 years
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
12-OAHSA Related Classifications
HY-113878 Related Classifications
Powered by Bioz